NCT02165943

Evaluation of Vitoss With and Without BMA for Benign Cavitary Lesions

A Combined Retrospective and Prospective Protocol to Evaluate Vitoss With and Without Bone Marrow Aspirate for Benign Cavitary Lesions

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Orthovita d/b/a Stryker · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a retrospective, two-arm study reviewing the healing of cavitary defects in patients treated with Vitoss alone versus those treated with Vitoss with bone marrow aspirate (BMA). There will be a prospective follow-up visit at 24+ months to evaluate lont-term healing in patients identified during the retrospective portion of the study. It is thought that the inclusion of BMA will facilitate the resorption of the graft material, leading to better long-term bone healing.

Conditions

• Bone Diseases

Interventions

Type	Name	Description
DEVICE	Vitoss	Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.

Timeline

• Start date: 2014-01-01
• Primary completion: 2014-12-01
• Completion: 2014-12-01
• First posted: 2014-06-18
• Last updated: 2014-06-18

Locations

1 site across 1 country: United States